Voyager Therapeutics, a Cambridge, Mass.-based gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS), completed a $60m Series B financing.The round was co-led by new investors Brookside Capital and Partner Fund Management with new participation from Wellington Management Company, LLP, Casdin Capital, LLC and two undisclosed blue chip investment funds.
The company intends to use the proceeds to advance the product pipeline, which includes five clinical and preclinical programs, as well as its adeno-associated virus (AAV) product engine.
Launched in 2014 by Steven Paul, M.D., president & chief executive officer, Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through investment in vector optimization and engineering, dosing and delivery techniques, as well as process development and production.
The company’s pipeline is focused on CNS diseases in dire need of effective new therapies, including Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich’s ataxia and Huntington’s disease.
FinSMEs
13/04/2015